ORIC Pharmaceuticals, Inc. (ORIC)
Healthcare
- Fundamental
- 2
- Sentiment
- 2
- Technical
- 4
Do Nothing: fundamentalScore 2 and qualitativeScore 2 are both below the required floor of 3, so the strategy blocks any bullish entry despite the strong technical breakout.
Company overview
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments. Its pipeline includes ORIC-533, an oral CD73 inhibitor, ORIC-944, a prostate cancer treatment targeting the polycomb repressive complex 2, and ORIC-114, an EGFR and HER2 inhibitor for brain-penetrant applications. The company collaborates with Voronoi Inc. and Mirati Therapeutics, Inc., and is headquartered in South San Francisco, California.
Fundamental
weakORIC Pharmaceuticals shows no revenue and persistent losses, with financials dominated by clinical and regulatory risks.
Clinical-stage biotech with strong liquidity and minimal debt, but no revenue and ongoing cash burn. Recent SEC filings indicate cash/investments around $388M with management projecting runway into the second half of 2028; meanwhile profitability and free cash flow remain negative (TTM ROE about −35% and FCF yield about −7%). The main risks are binary trial outcomes, regulatory approvals, and the potential need for additional financing/dilution.
Sentiment
weakMedia sentiment has turned slightly negative due to safety concerns, overshadowing previous optimism.
Media sentiment has deteriorated sharply from a bullish 30–90d baseline (polarity_score ≈ +0.49) to slightly negative in the last ~14d (≈ -0.10), driven by reported safety/tolerability concerns at higher doses for a prostate-cancer candidate plus bearish earnings/outlook framing. Moderate red-flag cap applied due to conflicting near-term signals (bearish safety headlines vs bullish sell-side price-target action); legal/regulatory scans showed no active investigations or material cases.
Technical
goodThe stock is in a strong uptrend, supported by positive momentum and trend indicators.
Strong post-catalyst uptrend: ORIC closed above all key moving averages and daily VWAP, MACD is positive and above signal, and ADX 54.88 confirms trend strength; the main technical blemish is short-term overbought momentum after a sharp run.
You’re looking at 2026-08-20 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.